Reduced intensity conditioning with Fludarabine, BCNU and Melphalan (FBM) for allogeneic hematopoietic cell transplantation in elderly AML patients: remission status at transplant predicts outcome

被引：0
作者：
Wais, V. [1 ]
Kuendgen, L. [2 ]
Bohl, S. [1 ]
von Harsdorf, S. [1 ]
Schlenk, R. F. [1 ]
Doehner, K. [1 ]
Teleanu, V. [1 ]
Bullinger, L. [1 ]
Drognitz, K. [2 ]
Moulin, J. -C. [2 ]
Binnenhei, M. [2 ]
Bentz, M. [2 ]
Doehner, H. [1 ]
Bunjes, D. [1 ]
Ringhoffer, M. [2 ]
Kuchenbauer, F. [1 ]
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Municipal Hosp Karlsruhe, Karlsruhe, Germany
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P616
引用
收藏
页码：S442 / S443
页数：2
相关论文
共 50 条
  • [41] Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity
    Chen, George L.
    Hahn, Theresa
    Wilding, Gregory E.
    Groman, Adrienne
    Hutson, Alan
    Zhang, Yali
    Khan, Usman
    Liu, Hong
    Ross, Maureen
    Bambach, Barbara
    Higman, Meghan
    Neppalli, Vishala
    Sait, Sheila
    Block, AnneMarie W.
    Wallace, Paul K.
    Singh, Anurag K.
    McCarthy, Philip L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (04) : 689 - 698
  • [42] Impact of age on outcome after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with Fludarabine/Busulfan
    Bethge, W. A.
    Federmann, B.
    Helwig, A.
    Faul, C.
    Vogel, W.
    Kanz, L.
    ONKOLOGIE, 2012, 35 : 129 - 129
  • [43] 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
    Sobecks, R. M.
    Dean, R.
    Rybicki, L. A.
    Chan, J.
    Theil, K. S.
    Macklis, R.
    Andresen, S.
    Kalaycio, M.
    Pohlman, B.
    Ferraro, C.
    Cherni, K.
    Sweetenham, J.
    Copelan, E.
    Bolwell, B. J.
    BONE MARROW TRANSPLANTATION, 2008, 42 (11) : 715 - 722
  • [44] IMPROVED OUTCOME OF ELDERLY PATIENTS AFTER REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
    Avraham, Perets G.
    Bains, T.
    Lemieux, A.
    Slater, S.
    Kovacsovics, T.
    Curtin, P.
    Gajewski, J.
    Meyers, G.
    Maziarz, R. T.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S347 - S348
  • [45] Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic Stem Cell Transplantation
    de Souza, Jonas A.
    Saliba, Rima M.
    Patah, Poliana
    Rondon, Gabriela
    Ribeiro, Rachel
    Silva, Leandro de Padua
    Qazilbash, Muzaffar H.
    Hosing, Chitra
    Popat, Uday
    Efebera, Yvonne
    Champlin, Richard E.
    de Lima, Marcos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (09) : 1094 - 1099
  • [46] 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
    R M Sobecks
    R Dean
    L A Rybicki
    J Chan
    K S Theil
    R Macklis
    S Andresen
    M Kalaycio
    B Pohlman
    C Ferraro
    K Cherni
    J Sweetenham
    E Copelan
    B J Bolwell
    Bone Marrow Transplantation, 2008, 42 : 715 - 722
  • [47] Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes
    Langenhorst, J. B.
    van Kesteren, C.
    van Maarseveen, E. M.
    Dorlo, T. P. C.
    Nierkens, S.
    Lindemans, C. A.
    de Witte, M. A.
    van Rhenen, A.
    Raijmakers, R.
    Bierings, M.
    Kuball, J.
    Huitema, A. D. R.
    Boelens, J. J.
    BLOOD ADVANCES, 2019, 3 (14) : 2179 - 2187
  • [48] Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Kamijo, Kimimori
    Shimomura, Yoshimitsu
    Kim, Sung-Won
    Ara, Takahide
    Ishikawa, Jun
    Eto, Tetsuya
    Hiramoto, Nobuhiro
    Mizuno, Ishikazu
    Kusumoto, Shigeru
    Ueda, Yasunori
    Matsuoka, Ken-ichi
    Onizuka, Makoto
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Kondo, Eisei
    BLOOD, 2022, 140 : 2393 - 2394
  • [49] Adverse Immunologic, Cytogenetic, and Molecular Features of AML in Elderly Patients Could Be Overcome by Allogeneic Hematopoietic Cell Transplantation Following Reduced Intensity Conditioning
    Al-Ali, Haifa Kathrin
    Jaekel, Nadja
    Krahl, Rainer
    Nehring, Claudia
    Becker, Cornelia
    Braunert, Leanthe
    Leiblein, Sabine
    Edelmann, Jeanett
    Franke, Georg
    Poenisch, Wolfram
    Lange, Thoralf
    Niederwieser, Dietger
    BLOOD, 2011, 118 (21) : 1321 - 1322
  • [50] Conditioning with fludarabine, BCNU, and melphalan in allogeneic stem cell transplantation results in reduced toxixcity and high activity against advanced hematologic malignancies
    Marks, Reinhard
    Potthoff', Karin
    Hahn, Joachim
    Ihorst, Gabriele
    Bertz, Hartmut
    Spyridonidis, Alexandros
    Holler, Ernst
    Finke, Jurgen
    BLOOD, 2007, 110 (11) : 901A - 901A
12345